To test this, we utilized Inducer of TGFBR2 Degradation-1 (ITD-1), a small-molecule TGFBR2 inhibitor that activates proteasome-dependent TGFBR2 protein degradation [38] and GBM cells engineered for doxycycline-induced shRNA-mediated TGFBR2 expression knockdown. The gene discussed is TGFBR2; the disease is glioblastoma.